Form 4: Pfizer Director Echevarria Acquires Phantom Stock Units

Pfizer Director Joseph Echevarria acquired 1,815.149 phantom stock units as deferred compensation, increasing his beneficial ownership to 144,989.542 units.

Summary

• Joseph Echevarria, a Director of Pfizer Inc. (PFE), acquired 1,815.149 phantom stock units.
• The transaction date for this acquisition was September 30, 2025.
• Each phantom stock unit represents one phantom share of common stock.
• These units were acquired at a price of $25.48 per unit.
• Following this transaction, Mr. Echevarria beneficially owns a total of 144,989.542 phantom stock units.
• The units represent deferred director's compensation, including dividend equivalents.
• Settlement of these units will occur in cash or common stock at the director's election following his retirement from the Board of Directors.

Sentiment

Score: 7

Explanation: The filing indicates a routine, positive event for the director, as it represents compensation and increased alignment with shareholder interests. For the company, it's a neutral event reflecting standard compensation practices.

Positives

• The acquisition of phantom stock units aligns the director's financial interests with the long-term performance of Pfizer's common stock.
• Deferred compensation through equity-linked instruments is a standard practice that can incentivize long-term commitment and strategic decision-making from board members.

Future Outlook

The phantom stock units represent deferred compensation that will be settled in cash or common stock at the director's election upon his retirement from the Board of Directors, indicating a future payout event tied to his tenure.

Industry Context

The use of phantom stock units as a form of deferred compensation for directors is a common practice within the pharmaceutical industry and large publicly traded companies. It serves to align the interests of board members with long-term shareholder value, consistent with broader corporate governance trends.

Comparison to Industry Standards

• The filing does not provide specific data points for direct comparison to other companies or projects. However, the use of phantom stock units as deferred director compensation is a common practice in large publicly traded companies to align director interests with shareholder value.

Related Party Transactions

• Acquisition of 1,815.149 phantom stock units by Joseph Echevarria, a Director of Pfizer Inc., as part of his deferred director's compensation plan. This is a standard transaction between the company and a related party (director).

Stakeholder Impact

• Shareholders: The transaction aligns the director's long-term financial interests with the company's stock performance, potentially encouraging decisions that benefit shareholder value.
• Director (Joseph Echevarria): Receives deferred compensation, increasing his equity-linked stake in the company.

Next Steps

• The phantom stock units will be settled in cash or common stock at the director's election following his retirement from the Board of Directors.

Key Dates

Recommendation

This Form 4 reports a routine compensation event for a director, which is not typically a catalyst for significant stock price movement. It indicates continued alignment of the director's interests with shareholders through deferred equity compensation, but does not provide new fundamental information to warrant a change in investment recommendation.

Keywords

Pfizer, PFE, Form 4, Insider Transaction, Phantom Stock Units, Director Compensation, Beneficial Ownership, Equity Compensation